0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Ascellahealth Launches Q3 2023 Specialty Rare Pipeline Digest Expert Resource For Fda Approval Status Of Specialty Pharmaceuticals And Cell Gene Therapies
News Feed
course image
  • 29 Sep 2023
  • Admin
  • News Article

AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™ Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q3 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics. This complimentary, digital source of industry information supports the specialty drug market needs of all stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that may impact millions of individuals living with or affected by rare disease or complex, chronic conditions.

“As the specialty drug pipeline continues to grow year-over-year, our dedication to providing industry stakeholders with critically important and timely updates remains paramount”

“As the specialty drug pipeline continues to grow year-over-year, our dedication to providing industry stakeholders with critically important and timely updates remains paramount,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “This latest edition of our Q3 2023 Specialty & Rare Pipeline Digest™ exemplifies our commitment to being at the forefront of disseminating and sharing knowledge, providing valuable insights and data to support our partners, clients, and the entire specialty pharmaceutical ecosystem.”

Dea Belazi, president & CEO, AscellaHealth, adds, “We are proud to provide The Q3 2023 Specialty & Rare Pipeline Digest™ that underscores our mission to support patients and clients with deep industry expertise to drive decision making. We applaud the relentless efforts of pharmaceutical manufacturers in developing and introducing these groundbreaking therapies. Our collaboration with all stakeholders ensures that these advancements translate into improved treatment access, patient care and outcomes."

AscellaHealth is a single-source partner providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for the rare disease / specialty population. Core Services include:

Pre-Commercialization & Market Access
Exclusive Distribution, Wholesale, and 3PL Services
International Specialty Pharmacy Fulfillment including Limited Distribution Drugs
Comprehensive HUB and Patient Support Services
Custom Compliance and Persistency Programs
Streamlined Prior Authorizations
Technology-based Patient Engagement
Integrated Copay and Financial Assistance Programs
Real-time Rx Data and Analytics
Specialty Pharmacy & Medical Benefit Management
Access the Q3 2023 Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form